Such results corroborate several recent studies that suggest serum GFAP and t‐tau only show elevations in more moderate to advanced stages of HD and, thus, are better for tracking disease severity and progression after motor onset, particularly in comparison with NfL [5, 9, 16, 17]. The gene discussed is GFAP; the disease is Huntington disease.